ITB 2025: Egypt Strengthens Tourism Ties with Germany at Berlin Fair
Egypt’s Minister of Tourism and Antiquities, Sherif Fathi, will present Egypt’s new tourism strategy at the ITB Berlin international travel trade fair, highlighting Germany’s pivotal role in the sector’s development. Germany continues to be Egypt’s largest source of visitors. In 2024, 1.7 million German tourists traveled to Egypt, marking a 5% increase from the previous year. “We are confident that the number of visitors will continue to rise in 2025,” stated Fathi, who has served as Minister of Tourism and Antiquities since July 2024. This will be his first ITB Berlin appearance as Minister.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250227385390/en/
The Grand Egyptian Museum (Photo: Business Wire)
In 2024, approximately 15.7 million international travelers visited Egypt—a 5% increase from the previous year—underscoring the country’s strategic vision of attracting 30 million tourists annually by 2030.
Egypt’s Tourism Highlights: History and Culture
Egypt is one of the world’s most popular travel destinations, renowned for its rich history, diverse culture, and breathtaking landscapes. The legacy of the pharaohs, including the last surviving Wonder of the Ancient World, attracts visitors passionate about history and ancient civilizations. The Red Sea, with its crystal-clear waters, is a top destination for divers and families alike. With world-class accommodations at affordable prices and excellent international flight connections, Egypt continues to be a premier travel hotspot.
The anticipated full opening of the Grand Egyptian Museum on July 3rd—the largest museum in the world dedicated to a single civilization—will be a highlight of this year. After three decades of planning and restoration, the museum partially opened on October 16, 2024. While some sections remain under development, visitors can already explore the Grand Hall, staircases, gardens, and select exhibition spaces. During the museum’s pre-opening phase in 2024, more than 300,000 guests visited its main halls.
Health and Wellness
Egypt has also emerged as a leading destination for health and wellness tourism. From luxury resorts on the Red Sea to remote desert oases, the country offers world-class wellness experiences. Known for its mineral-rich hot springs and therapeutic waters, Egypt provides treatments for various ailments, including skin conditions, respiratory diseases, and rheumatism. Notable wellness destinations include:
- Siwa Oasis, home to over 200 natural springs used for healing treatments.
- Bahariya and Kharga Oases, featuring sulfur-rich thermal waters.
- Aswan, known for its prestigious spa resorts such as Kato Doo Wellness and The Zen Wellness.
Sustainable Tourism Development
Egypt is committed to sustainable development of its tourism infrastructure and the preservation of its cultural heritage. Protecting the Red Sea’s unique biodiversity is a central pillar of Egypt’s responsible tourism strategy. Environmental certification programs for resorts play an integral role in these efforts, particularly in coastal regions stretching from El Gouna to Marsa Alam.
As one of the key participants at ITB Berlin 2025, Egypt's Tourism Authority invites journalists to the following press conference:
Date: Tuesday, March 4, 2025
Time: 15:00 hrs
Location: Messe Berlin Booth M4, CityCube Messedamm 22, 14055 Berlin
For more information, visit: https://www.experienceegypt.eg/en
About the About the Egyptian Tourism Authority
The Egyptian Tourism Authority (ETA) was established in 1981 to boost international tourism by highlighting Egypt's long history and promoting the country’s many tourist attractions. The ETA's mission also includes increasing domestic tourism, raising awareness of tourism throughout the country, and strengthening the connection between Egyptians and their heritage. The ETA focuses on the diversity of attractions and destinations within Egypt and on developing marketing strategies and programmes to promote tourism, as well as providing technical and marketing support. It also organises and sponsors touristic, sporting, social and cultural events throughout the country. The ETA Board of Directors is chaired by the Minister of Tourism.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250227385390/en/
Contacts
Kamila Giraldo
Account Manager
e-mail: egypttourism@mcgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ENHERTU ® Recommended for Approval in the EU by CHMP for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy28.2.2025 15:00:00 EET | Press release
Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) ENHERTU® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 low (IHC 1+ or IHC 2+/ISH-) or HER2 ultralow (IHC 0 with membrane staining) breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast06 phase 3 trial presented at the 2024 American Society of Clinical Oncology (#ASCO24) Annual Meeting and pu
Radisys Expands Small Cell Portfolio with Qualcomm Dragonwing FSM200 Platform for FR1 and FR228.2.2025 15:00:00 EET | Press release
Radisys® Corporation, a global leader of open telecom solutions, announced the availability of its award-winning Connect RAN software on the Qualcomm Dragonwing™ FSM200 Platform for both FR1 and FR2. The solution leverages baseband and advanced Radio capabilities of the Dragonwing FSM200 platform to address high performance/capacity use cases with advanced features required in various market segments, including MNOs, enterprise, Fixed Wireless Access (FWA), private 5G, Industry 4.0 and home networks. Radisys Connect RAN software on the Qualcomm Dragonwing™ FSM100 platform is already globally deployed for various use cases. Radisys' Connect RAN 5G solution offers a comprehensive feature set, fully interoperable with a wide ecosystem and robust manageability support, enabling customers to deploy small cells in multiple verticals at reduced operational and capital expenses with a quick time-to-market. Highlights Radisys demonstrated continued leadership in mmWave RAN on Dragonwing FSM100
Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO ® in Combination With Ivacaftor for People With Cystic Fibrosis to Include Rare Mutations28.2.2025 14:22:00 EET | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the label expansion of KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor for the treatment of people with cystic fibrosis (CF) aged 2 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “We are thrilled by the positive CHMP opinion in support of expanding the KAFTRIO in combination with ivacaftor indication to include all CF patients 2 years and older who make CFTR protein,” said Fosca De Iorio, M.D., Vice President, International Medical Affairs at Vertex. “If approved, thousands of additional patients across Europe will be eligible for a CFTR modulator, bringing us closer than ever to our goal of getting treatments that address the underlying cause of the disease to all people living with CF.” In the Eur
SINOVAC Announces New Board Pursuant to Privy Council Judgment and Order28.2.2025 14:00:00 EET | Press release
Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that SINOVAC has received on February 8, 2025 a formal court order (the “Order”) from the Privy Council following the previously announced Privy Council Judgment (the “Judgment”) which ruled, among others, that (i) the slate of nominees proposed by a group of shareholders at the 2018 Annual General Meeting was rightfully elected to the board of directors of SINOVAC and (ii) the Company’s Rights Agreement (also known as poison pill agreement) was invalid. Upon the receipt of the Order, SINOVAC has begun to implement the Judgment and the Order. As the Company's Rights Agreement is void, all the exchange shares issued pursuant to the Rights Agreement (the “Exchange Shares”), including 27,777,341 common shares and all 14,630,813 Convertible Series B Preferred Shares of SINOVAC, held by the 2019 Rights Exchange Trust, are void and will be cancelled. The
Delta-Fly Pharma, Inc.: Progress of Development Status of the Combination Study of DFP-10917 with Venetoclax28.2.2025 13:21:00 EET | Press release
Following to the previous information on Dec. 9th. in 2024, we are excited to share our latest development status. Regarding the Phase I/II clinical trial of DFP-10917 in combination with Venetoclax (VEN) in patients with acute myeloid leukemia (AML) in second-line therapy (NCT06382168), the Data Management Committee (DMC) has approved the tolerability of all six patients in the Phase I (dose finding) portion of the Phase I/II study, and we are moving to the Phase II portion of the trial for efficacy testing as of today, on 28th Feb., 2025. We are pleased to inform that we already have multiple potential patients waiting to participate in the trial. Please take notice of our own innovative approach for miserable cancer patients and contact us. View source version on businesswire.com: https://www.businesswire.com/news/home/20250228414852/en/
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom